Answers are grounded in this paper and cite their sources.
Gaucher disease is a rare autosomal recessive disorder characterized by the defective function of the catabolic enzyme -glucocerebrosidase causing accumulation of its substrate, glucocerebroside in the macrophages resulting into the hematological, visceral, bone and neurologic system deformities.The clinical signs and symptoms are neurological dysfunctions, bone infarcts and malformations, hepatosplenomegaly, and hypersplenism causing anemia, neutropenia, and thrombocytopenia.Gaucher disease is classified into three broad phenotypes based upon the presence or absence of neurological involvement and classified into type 1, 2, and 3. Disease-specific treatment consists of intravenous enzyme replacement therapy (ERT) using one of the currently available molecules (imiglucerase, velaglucerase, or taliglucerase).Orally administered inhibitors of glucosylceramide biosynthesis can also be used (miglustat or eliglustat).A diagnosis of GD can be confirmed by demonstrating the deficiency of acid glucocerebrosidase activity in leukocytes.Mutations in the GBA1 gene should be identified as they may be of prognostic value in some cases.Patients with type-1 GD carry GBA1 mutation.These patients are more predisposed to develop Parkinson's disease, and the risk of neoplasia.In this review we have provided a short description of Gaucher disease, its subtypes, important mutations involved, and a brief overview of how Gaucher disease affects the outcome of pregnancy.Gaucher disease in pregnancy is an important area to be analyzed in depth, as patients undergoing pregnancy may have additional risk of developing anemia thrombocytopenia etc., that may lead to the postpartum bleeding.
No takes yet. Share an insight, caveat, or question.
Suraksha Agrawal (2023) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: